NBCI Seeks Newly Diagnosed Men and Women Breast Cancer Patients Who Are Members of Our Churches
1 Peter 5:7
4And when the chief Shepherd shall appear, ye shall receive a crown of glory that fadeth not away. 5Likewise, ye younger, submit yourselves unto the elder. Yea, all of you be subject one to another, and be clothed with humility: for God resisteth the proud, and giveth grace to the humble. 6Humble yourselves theref the mighty hand of God, that he may exalt you in due time: 7Casting all your care upon him; for he careth for you.
We would like to inform you of a study for men and women with breast cancer using Ribociclib (Kisqali™ ) and Letrozole (Femara™ ), two drugs that are already approved by the FDA (the US Food and Drug Administration). This combination of drugs is available on the market for certain breast cancer patients, but is still considered experimental for others. This study is called CompLEEment-1 (protocol number CLEE011A2404).
Study Purpose: The goal of this study is to better understand the safety and effectiveness of Ribociclib in combination with Letrozole for patients with hormone receptor positive (ER+/PR+)/HER2- advanced or metastatic breast cancer.
Here is the population of individuals we are looking for:
- Men, premenopausal, and postmenopausal women with a certain type of advanced breast cancer, called hormone receptor positive (ER+/PR+)/HER2- breast cancer.
- Patients with advanced or metastatic breast cancer, which typically means that they have had to try different medications or that they were diagnosed late.
To determine whether you are eligible for this study or to find a doctor's office closest to you, please contact: 1-855-413-9165 to speak with a medical information specialist.
Discuss this fact sheet with your doctor.